Add-on Acquisition • Life Science

Vaxil Bio Acquires Short Wave

On October 14, 2021, Vaxil Bio acquired life science company Short Wave

Acquisition Context

This is Vaxil Bio’s 1st transaction in the Life Science sector.
This is Vaxil Bio’s 1st transaction in Israel.

Explore All 3111 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 14, 2021
Target	Short Wave
Sector	Life Science
Buyer(s)	Vaxil Bio
Deal Type	Add-on Acquisition

Target Company

Short Wave

Israel

Short Wave is an Israeli-based pre-clinical stage biotech company focused on the development of IP-protected formulations and delivery methods of psychedelics-based medicine to treat mental illness, chronic pain, and neurodegenerative diseases. Short Wave is based in Israel.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Vaxil Bio

Toronto, Ontario, Canada

Category	Company
Founded	2006
Sector	Life Science

DESCRIPTION

Vaxil Bio is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. Vaxil Bio was founded in 2006 and is based in Toronto, Ontario.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Israel	1 of 1
Year: 2021	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Israel M&A - 2021 M&A